IRCT20180618040127N4招募中3 期
The effect of Dalfampridine on dysfunction of walking in patients with HTLV-1-induced myelopathy
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •Positive serology for Human T-cell Lymphotropic Virus Type-1 (HTLV-1)
- •Occurrence of spastic paraparesia
- •Existence of anti HTLV-1 antibody in cerebrospinal fluid
- •Rule out of other etiologies of spastic paraparesia
- •Motor Disability Grading (MDG) less than 9
- •Informed consent for participating in the study
排除标准
- •Existence of other active and latent infections
- •Receiving other drug which influence immune system
- •Existence of any history of seizures or epilepsy or other seizure disorders
研究者
相似试验
招募中
3 期
Effect of Dalfampridine in Treatment of Spinal Cord InjuryThoracic Spinal Cord Injury.Injury of spinal cord, level unspecifiedT09.3IRCT20231019059767N1Mashhad University of Medical Sciences52
招募中
3 期
Dalfampridine in improving spasticity in patients with severe brain traumaSevere traumatic brain injury.Diffuse traumatic brain injuryS06.2IRCT20221108056446N2Esfahan University of Medical Sciences80
进行中（未招募）
不适用
Effects of dalfampridine on mobility in the context of daily lifeEUCTR2014-003498-41-ATMedical University of Vienna
招募中
不适用
Dalfampridine in Egyptian Patients With Multiple SclerosisMultiple SclerosisNCT05730738Ain Shams University100
已完成
不适用
Dalfampridine and Gait in Spinocerebellar AtaxiasSpinocerebellar Ataxias Type 1Spinocerebellar Ataxias Type 2Spinocerebellar Ataxias Type 3Spinocerebellar Ataxias Type 6NCT01811706University of Florida20